CompletedPhase 2NCT00118352

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Studying Acute undifferentiated leukemia

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fred Hutchinson Cancer Center
Principal Investigator: Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Intervention: alemtuzumab(biological)
Enrollment: 12 enrolled
Eligibility: 74 years · All sexes
Timeline: 2005 – 2015

Study locations (2)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
University of Torino, Torino, Italy

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00118352 on ClinicalTrials.gov

Other trials for Acute undifferentiated leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06466395
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
M.D. Anderson Cancer Center

See all trials for Acute undifferentiated leukemia →

← Back to all trials